{"analyses":[{"ciLowerLimit":"0.607","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.943","estimateComment":"Stratified","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0118","pValueComment":"Stratified","paramType":"Hazard Ratio (HR)","paramValue":"0.757","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.96","upperLimit":"4.47","value":"4.07"},{"groupId":"OG001","lowerLimit":"2.60","upperLimit":"2.96","value":"2.76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"221"}],"units":"Participants"}],"description":"PFS defined as time from first day of therapy to first evidence of disease progression defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions, with reference being the smallest sum on study and plus absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If participant does not have complete baseline disease assessment, then PFS time was censored at date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for participant. If participant is not known to have died or have objective progression as of data inclusion cutoff date for analysis, PFS time was censored at last adequate tumor assessment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ramucirumab (10 mg/kg) IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + Docetaxel"},{"description":"Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Placebo + Docetaxel"}],"paramType":"MEDIAN","populationDescription":"The first randomized participants. Censored participants: Ramucirumab + Docetaxel = 58, Placebo + Docetaxel =38.","reportingStatus":"POSTED","timeFrame":"Randomization to Radiological Disease Progression or Death from Any Cause (Up to 18 Months)","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Months"}